natgillin/translations-raw huggingface dataset:
Patients should be told about the signs and symptoms of GI undesirable effects and what steps to take if they occur.
Bolesnicima treba objasniti znakove i simptome mogućih gastrointestinalnih nuspojava i što učiniti ako se pojave. (vidjeti dio 4.8).
Data from epidemiological studies suggest an increased risk of miscarriage and of cardiac malformation and gastroschisis after use of a prostaglandin synthesis inhibitor in early pregnancy.
Podaci iz epidemioloških ispitivanja upućuju da se, nakon primjene inhibitora sinteze prostaglandina u ranoj trudnoći, povećava rizik od pobačaja, srčanih malformacija i gastroshize.
Patients were randomised to clopidogrel (300 mg loading dose followed by 75 mg/day, N=6,259) plus ASA (75-325 mg once daily) or ASA alone (N=6,303), (75-325 mg once daily) and other standard therapies.
Bolesnici su randomizirani u skupine koje su primale klopidogrel (udarna doza od 300 mg, a nakon toga 75 mg/dan, N=6259) plus ASK (75 mg do 325 mg jedanput dnevno) ili samu ASK (N=6303, 75 mg do 325 mg jedanput dnevno), uz drugu standardnu terapiju.
The most common side effect which has been seen with Clopidogrel/Acetylsalicylic acid Mylan is bleeding.
Najčešća nuspojava lijeka Klopidogrel/acetilsalicilatna kiselina Mylan jest krvarenje.
Glycerol monocaprylocaprate (E422) Sodium lauril sulfate
Glicerol monokaprilokaprat (E422)
Patients should also be told that it might take longer than usual to stop bleeding when they take Clopidogrel/Acetylsalicylic acid Mylan, and that they should report any unusual bleeding (site or duration) to their physician.
Bolesnicima koji uzimaju lijek Klopidogrel/acetilsalicilatna kiselina Mylan potrebno je objasniti da će krvarenje možda trajati dulje nego obično te da moraju obavijestiti liječnika ako se pojavi bilo kakvo neočekivano krvarenje (mjesto i trajanje krvarenja).
Bullous dermatitis (toxic epidermal necrolysis, Stevens Johnson Syndrome, erythema multiforme, acute generalised exanthematous pustulosis (AGEP)), angioedema, druginduced hypersensitivity syndrome, drug rash with eosinophilia and systemic symptoms (DRESS), rash erythematous or exfoliative, urticaria, eczema, lichen planus, fixed eruption*
bulozni dermatitis (toksična epidermalna nekroliza, Stevens Johnsonov sindrom, erythema multiforme, akutna generalizirana egzantematozna pustuloza (AGEP)), angioedem, sindrom preosjetljivosti izazvane lijekom, kožni osip uzrokovan lijekom s eozinofilijom i sistemskim simptomima (engl.
• Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction) including patients undergoing a stent placement following percutaneous coronary intervention
u bolesnika s akutnim koronarnim sindromom bez elevacije ST-segmenta (nestabilna angina ili non-Q-infarkt miokarda), uključujući bolesnike kojima se ugrađuje stent nakon perkutane koronarne intervencije,
The concomitant administration of Clopidogrel/Acetylsalicylic acid Mylan with oral anticoagulants is not recommended since it may increase the intensity of bleeding (see section 4.5).
Ne preporučuje se istodobna primjena lijeka Klopidogrel/acetilsalicilatna kiselina Mylan i drugih oralnih antikoagulansa, jer to može pojačati intenzitet krvarenja (vidjeti dio 4.5).
In addition, increased incidences of various malformations, including cardiovascular, have been reported in animals given a prostaglandin synthesis inhibitor during the organogenetic period.
Nadalje, u životinja koje su tijekom perioda organogeneze primale inhibitore sinteze prostaglandina, prijavljena je veća učestalost različitih malformacija uključujući kardiovaskularne.
Therapeutic experience is limited in patients with moderate hepatic disease who may have bleeding diatheses (see section 4.4).
Terapijsko iskustvo u bolesnika s umjerenim oštećenjem funkcije jetre koji bi mogli imati povećanu sklonost krvarenju je ograničeno (vidjeti dio 4.4).
The number of patients experiencing the co-primary endpoint (CV death, MI, stroke or refractory ischaemia) was 1,035 (16.5%) in the clopidogrel plus ASA group and 1,187 (18.8%) in the ASA group, a 14% relative risk reduction (95% CI of 6%-21%, p=0.0005) for the clopidogrel plus ASA group.
U skupini koja je primala klopidogrel plus ASK bilo je 1035 (16,5%) bolesnika sa koprimarnim ishodom (smrt zbog kardiovaskularnih uzroka, infarkt miokarda, moždani udar ili refraktorna ishemija), odnosno 1187 (18,8%) bolesnika u skupini koja je primala samo ASK, što znači smanjenje relativnoga rizika od 14% (95% CI: 6% - 21%, p=0,0005) u skupini koja je primala klopidogrel plus ASK.
Therapeutic experience is limited in patients with mild to moderate renal impairment (see section 4.4).
Terapijsko iskustvo u bolesnika s blagim do umjerenim oštećenjem funkcije bubrega je ograničeno (vidjeti dio 4.4).
Experimental data suggest that ibuprofen may inhibit the effect of low dose aspirin on platelet aggregation when they are dosed concomitantly.
Eksperimentalni podaci upućuju da, ako su primijenjeni istodobno, ibuprofen može inhibirati učinak niske doze acetilsalicilatne kiseline na agregaciju trombocita.
The primary outcome, a composite of cardiovascular death, stroke, urgent revascularization, and BARC (Bleeding Academic Research Consortium) bleeding ≥2 at 1 year post ACS, occurred in 43 patients (13.4%) in the de-escalated DAPT group and in 85 patients (26.3%) in the unchanged DAPT group (p<0.01).
Bleeding Academic Research Consortium) stupnja krvarenja ≥ 2 u prvoj godini nakon akutnog koronarnog sindroma dogodio se u 43 bolesnika (13,4%) u skupini s de-eskaliranim DAPTom i u 85 bolesnika (26,3%) u skupini s nepromijenjenim DAPT-om (p<0,01).
Patients received clopidogrel (300 mg loading dose, followed by 75 mg/day, n=1,752) plus ASA or ASA alone (n=1,739), (150 to 325 mg as a loading dose, followed by 75 to 162 mg/day), a fibrinolytic agent and, when appropriate, heparin.
Bolesnici su primali klopidogrel (prvo udarnu dozu od 300 mg, a nakon toga dozu od 75 mg na dan, N=1725) plus ASK ili samo ASK (N=1739, 150 mg do 325 mg kao udarnu dozu nakon čega je slijedila doza od 75 mg do 162 mg na dan) uz fibrinolitik i, po potrebi, heparin.
Valproic acid
Valproatna kiselina
Uricosurics (benzbromarone, probenecid, sulfinpyrazone) Caution is required because ASA may inhibit the effect of uricosuric agents through competitive elimination of uric acid.
Potreban je oprez jer ASK inhibira učinak urikozurika putem kompetitivne eliminacije mokraćne kiseline.
Croscarmellose sodium Hydroxypropylcellulose Colloidal anhydrous silica Talc
Kroskarmeloza natrij Hidroksipropilceluloza Silicijev dioksid, koloidni, bezvodni Talk
NN:
ASK:
From the beginning of the sixth month of pregnancy, all prostaglandin synthesis inhibitors may expose: the foetus to: cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); renal dysfunction, which may progress to renal failure with oligo-hydroamniosis;
• fetus: - kardiopulmonalnoj toksičnosti (s preranim zatvaranjem duktusa arteriosusa i plućnom hipertenzijom); - bubrežnoj disfunkciji, koja se može razviti u bubrežno zatajenje sa oligohidroamnionom;
The ASA in Clopidogrel/Acetylsalicylic acid Mylan is rapidly hydrolysed in plasma to salicylic acid, with a half-life of 0.3 to 0.4 hours for ASA doses from 75 to 100 mg. Salicylic acid is primarily conjugated in the liver to form salicyluric acid, a phenolic glucuronide, an acyl glucuronide, and a number of minor metabolites.
ASK u lijeku Klopidogrel/acetilsalicilatna kiselina Mylan brzo se u plazmi hidrolizira u salicilatnu kiselinu koja ima poluvijek od 0,3 do 0,4 sata za doze ASK od 75 do 100 mg.
ASA group, a 20% relative risk reduction (RRR) (95% CI of 10%-28%; p=0.00009) for the clopidogrel plus ASA group [17% relative risk reduction when patients were treated conservatively, 29% when they underwent percutaneous transluminal coronary angioplasty (PTCA) with or without stent and 10% when they underwent coronary artery bypass graft (CABG)].
U skupini koja je primala klopidogrel plus ASK bilo je 582 (9,3%) bolesnika s primarnim ishodom (smrt zbog kardiovaskularnih uzroka, infarkt miokarda ili moždani udar), a u skupini koja je primala samo ASK 719 (11,4%) bolesnika, što je 20%-tno smanjenje relativnog rizika (95% CI; 10% - 28%; p=0,00009) u skupini koja se liječila klopidogrelom plus ASK [17% smanjenje relativnoga rizika u bolesnika koji su liječeni konzervativno, 29% u bolesnika podvrgnutih perkutanoj transluminalnoj koronarnoj angioplastici (PTCA) s ili bez ugradnje stenta i 10% u bolesnika podvrgnutih aortokoronarnom premoštenju (CABG)].
What you need to know before you take Clopidogrel/Acetylsalicylic acid Mylan Do not take Clopidogrel/Acetylsalicylic acid Mylan
Što morate znati prije nego počnete uzimati lijek Klopidogrel/acetilsalicilatna kiselina Mylan
if you have any stomach or abdominal pain or bleeding in the stomach or bowels (red stools or black stools).
• Obavijestite svog liječnika ako planirate kirurški zahvat (uključujući stomatološke zahvate), ako imate želučane ili abdominalne bolove ili krvarenje u želucu ili crijevima (crvena ili crna stolica).
The bottles contain a desiccant.
U bocama se nalazi sredstvo za sušenje.
It is unknown whether ASA dose in Clopidogrel/Acetylsalicylic acid Mylan alters fertility.
Nije poznato utječe li doza ASK u lijeku Klopidogrel/acetilsalicilatna kiselina Mylan na plodnost.
While you are taking Clopidogrel/Acetylsalicylic acid Mylan
Dok uzimate lijek Klopidogrel/acetilsalicilatna kiselina Mylan
Patients should be counselled about the risks of gastrointestinal injury and bleeding while taking clopidogrel plus ASA with alcohol, especially if alcohol consumption is chronic or heavy.
Bolesnike treba savjetovati o rizicima od gastrointestinalnog oštećenja i krvarenja ako konzumiraju alkohol tijekom liječenja klopidogrelom i ASK, osobito ako je konzumacija alkohola kronična ili obilna. (vidjeti dio 4.5).
Respiratory tract bleeding (haemoptysis, pulmonary haemorrhage), bronchospasm, interstitial pneumonitis, noncardiogenic pulmonary oedema with chronic use and in the context of a hypersensitivity reaction due to acetylsalicylic acid*, eosinophilic pneumonia.
Poremećaji dišnog sustava, prsišta i sredoprsja epistaksa krvarenje u dišnom sustavu (hemoptiza, plućno krvarenje), bronhospazam, intersticijski pneumonitis, nekardiogeni edem pluća pri kroničnoj primjeni i u sklopu reakcije preosjetljivosti na acetilsalicilatnu kiselinu*, eozinofilna pneumonija
Although the administration of clopidogrel 75 mg/day did not modify the pharmacokinetics of S-warfarin or International Normalised Ratio (INR) in patients receiving long-term warfarin therapy, coadministration of clopidogrel with warfarin increases the risk of bleeding because of independent effects on haemostasis.
International Normalised Ratio) u bolesnika koji primaju dugotrajnu terapiju varfarinom, istodobna primjena klopidogrela s varfarinom povećava rizik od krvarenja zbog nezavisnih učinaka na hemostazu.
HDPE bottles with white opaque polypropylene screw cap with aluminium induction sealing liner wad and desiccant containing 100 film-coated tablets.
100 filmom obloženih tableta u boci od polietilena visoke gustoće (HDPE) s bijelim neprozirnim polipropilenskim navojnim zatvaračem s aluminijskom zaštitnom folijom i sredstvom za sušenje.
Appropriate therapy should be considered if bleedings are observed.
Ako se primijeti krvarenje, treba odmah odrediti primjerenu terapiju.
Hearing loss* or tinnitus*
Poremećaji uha i labirinta vrtoglavica gubitak sluha* ili tinitus*
Therefore Clopidogrel/Acetylsalicylic acid Mylan should be used with caution in these patients.
Stoga, u tih bolesnika, lijek Klopidogrel/acetilsalicilatna kiselina Mylan treba primjenjivati s oprezom.
• nicorandil, medicine to treat cardiac chest pain.
• nikorandil, lijek za liječenje boli u prsnom košu uzrokovane problemima sa srcem,
Haemodialysis is the preferred treatment for severe intoxication.
Preporučeni postupak za liječenje teške intoksikacije je hemodijaliza.
How to store Clopidogrel/Acetylsalicylic acid Mylan
Kako uzimati lijek Klopidogrel/acetilsalicilatna kiselina Mylan
Clopidogrel/Acetylsalicylic acid Mylan must not be used in patients with severe hepatic impairment (see section 4.3).
Klopidogrel/acetilsalicilatna kiselina Mylan ne smije se primjenjivati u bolesnika s teškim oštećenjem funkcije jetre (vidjeti dio 4.3).
GI undesirable effects including stomach pain, heartburn, nausea, vomiting, and GI bleeding may occur.
Nuspojave u gastrointestinalnom sustavu uključuju bol u trbuhu, žgaravicu, mučninu, povraćanje, a može se pojaviti i gastrointestinalno krvarenje.
BOTTLE LABEL
BOCA (NALJEPNICA)
th month of pregnancy), the dose should be kept as low and duration of treatment as short as possible.
Ako acetilsalicilatnu kiselinu uzimaju žene koje pokušavaju začeti ili žene do 24-og tjedna amenoreje (5-og mjeseca trudnoće), doza treba biti što niža, a trajanje liječenja što kraće.
th month of pregnancy), acetylsalicylic acid should not be given unless clearly necessary.
Acetilsalicilatna kiselina se ne preporučuje do 24-og tjedna amenoreje (5-og mjeseca trudnoće), osim ako je primjena neophodna.
Clopidogrel/Acetylsalicylic acid Mylan 75 mg/100 mg film-coated tablets contain Allura Red AC Allura Red AC may cause allergic reactions.
Klopidogrel/acetilsalicilatna kiselina Mylan filmom obložene tablete od 75 mg/100 mg sadrže boju Allura Red AC koja može izazvati alergijske reakcije.
Upper gastrointestinal disorders (oesophagitis, oesophageal ulceration, perforation, erosive gastritis, erosive duodenitis; gastroduodenal ulcer/perforations)*; lower gastrointestinal disorders (small [jejunum and ileum] and large [colon and rectum] intestinal ulcers, colitis and intestinal perforation)*; upper gastro-intestinal symptoms* such as gastralgia (see section 4.4); these ASA related GI reactions may or may not be associated with haemorrhage, and may occur at any dose of acetylsalicylic acid and in patients with or without warning symptoms or a previous history of serious GI events*.
Vrlo rijetko, nepoznato crijeva)*; simptomi u gornjem gastrointestinalnom traktu*, npr. gastralgija (vidjeti dio 4.4); ove gastrointestinalne reakcije povezane s ASK mogu ili ne moraju biti udružene s krvarenjem, i mogu se javiti pri bilo kojoj dozi acetilsalicilatne kiseline i u bolesnika s ili bez upozoravajućih simptoma ili ranijih ozbiljnih gastrointestinalnih događaja u povijesti bolesti*.
Clopidogrel/Acetylsalicylic acid Mylan must not be used in patients with severe renal impairment (see section 4.3).
Klopidogrel/acetilsalicilatna kiselina Mylan ne smije se primjenjivati u bolesnika s teškim oštećenjem funkcije bubrega (vidjeti dio 4.3).
5.2 Pharmacokinetic properties
5.2 Farmakokinetička svojstva Klopidogrel:
Thrombotic thrombocytopenic purpura (TTP) (see section 4.4), bone marrow failure*, aplastic anaemia, pancytopenia, bicytopenia*, agranulocytosis, severe thrombocytopenia, acquired haemophilia A, granulocytopenia, anaemia, haemolytic anaemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency* (see section
*, aplastična anemija, pancitopenija, bicitopenija agranulocitoza, teška trombocitopenija, stečena hemofilija A, granulocitopenija, anemija, hemolitička anemija u bolesnika s nedostatkom glukoza-6-fosfat dehidrogenaze (G6PD)
No genotoxicity or clastogenicity issues of concern have been found with ASA.
U primjeni ASK nisu zabilježeni zabrinjavajući slučajevi genotoksičnosti i klastogeneze.
What Clopidogrel/Acetylsalicylic acid Mylan contains
Klopidogrel/acetilsalicilatna kiselina Mylan sadrži natrij
Clopidogrel/Acetylsalicylic acid Mylan 75 mg/100 mg film-coated tablets Pink, oval shaped, biconvex, film-coated tablets, approximately 14.8 mm x 7.8 mm debossed with “CA3” on one side of the tablet and “M” on the other side.
Klopidogrel/acetilsalicilatna kiselina Mylan 75 mg/100 mg filmom obložene tablete Ružičaste, ovalne i bikonveksne filmom obložene tablete, veličine približno 14,8 mm × 7,8 mm, s utisnutim oznakama „CA3” na jednoj i „M” na drugoj strani.
Clopidogrel/Acetylsalicylic acid Mylan 75 mg/75 mg film-coated tablets Yellow, oval shaped, biconvex, film-coated tablets, approximately 14.5 mm x 7.4 mm debossed with “CA2” on one side of the tablet and “M” on the other side.
Klopidogrel/acetilsalicilatna kiselina Mylan 75 mg/75 mg filmom obložene tablete Žute, ovalne i bikonveksne filmom obložene tablete, veličine približno 14,5 mm × 7,4 mm, s utisnutim oznakama „CA2” na jednoj i „M” na drugoj strani.
Since SSRIs affect platelet activation and increase the risk of bleeding, the concomitant administration of SSRIs with clopidogrel should be undertaken with caution.
Selektivni inhibitori ponovne pohrane serotonina (SSRI) Budući da lijekovi iz skupine SSRI utječu na aktivaciju trombocita i povećavaju rizik od krvarenja, potreban je oprez prilikom istodobne primjene SSRI i klopidogrela.
Tablet coating: hypromellose, triacetin, talc, poly (vinyl alcohol) (partially hydrolysed), titanium dioxide (E171), glycerol monocaprylocaprate (E422), sodium lauril sulfate, Allura Red AC (E129) (see section 2 ‘Clopidogrel/Acetylsalicylic acid Mylan contains Allura Red AC')
Ovojnica tablete: hipromeloza, triacetin, talk, poli(vinilni alkohol) (djelomično hidroliziran), titanijev dioksid (E171), glicerol monokaprilokaprat (E422), natrijev laurilsulfat, Allura Red AC (E129) (vidjeti dio 2 „Klopidogrel/acetilsalicilatna kiselina Mylan sadrži boju Allura Red AC“) Kako Klopidogrel/acetilsalicilatna kiselina Mylan izgleda i sadržaj pakiranja Klopidogrel/acetilsalicilatna kiselina Mylan 75 mg/75 mg filmom obložene tablete su žute, ovalne, bikonveksne tablete s utisnutom oznakom „CA2“ na jednoj i „M“ na drugoj strani.
Rash, pruritus, skin bleeding (purpura)
Poremećaji kože i potkožnog tkiva stvaranje modrica osip, svrbež, krvarenja na koži (purpura)
Clopidogrel/Acetylsalicylic acid Mylan 75 mg/100 mg
Klopidogrel/acetilsalicilatna kiselina Mylan 75 mg/100 mg
Clopidogrel/Acetylsalicylic acid Mylan 75 mg/75 mg
Klopidogrel/acetilsalicilatna kiselina Mylan 75 mg/75 mg
Clopidogrel/Acetylsalicylic acid Mylan 75 mg/75 mg film-coated tablets Clopidogrel/Acetylsalicylic acid Mylan should be given as a single daily 75 mg/75 mg dose.
Klopidogrel/acetilsalicilatna kiselina Mylan 75 mg/75 mg filmom obložene tablete Klopidogrel/acetilsalicilatna kiselina Mylan daje se u jednokratnoj dnevnoj dozi od 75 mg/75 mg.
Gastric ulcer and duodenal ulcer, gastritis, vomiting, nausea, constipation, flatulence
Poremećaji probavnog sustava gastrointestinalno krvarenje, proljev, bol u abdomenu, dispepsija ulkus želuca i dvanaesnika, gastritis, povraćanje, mučnina, konstipacija, flatulencija retroperitonealno krvarenje
Clopidogrel/Acetylsalicylic acid Mylan 75 mg/75 mg film-coated tablets EU/1/19/1395/001 - Cartons of 28 film coated tablets in aluminium blister packs EU/1/19/1395/002 - Cartons of 30 film coated tablets in aluminium blister packs EU/1/19/1395/003 - Cartons of 28 x 1 (unit dose) film coated tablets in aluminium blister packs EU/1/19/1395/004 - Cartons of 30 x 1 (unit dose) film coated tablets in aluminium blister packs EU/1/19/1395/005 - Cartons of 100 film coated tablets in HDPE bottle packs
Klopidogrel/acetilsalicilatna kiselina Mylan 75 mg/75 mg filmom obložene tablete EU/1/19/1395/001 - kutije s 28 filmom obloženih tableta u aluminijskim blisterima EU/1/19/1395/002 - kutije s 30 filmom obloženih tableta u aluminijskim blisterima EU/1/19/1395/003 - kutije s 28 x 1 (jedinična doza) filmom obloženih tableta u aluminijskim blisterima
Clopidogrel/Acetylsalicylic acid Mylan 75 mg/75 mg film-coated tablets Each film-coated tablet contains 75 mg of clopidogrel (as hydrogen sulphate) and 75 mg of acetylsalicylic acid (ASA).
Klopidogrel/acetilsalicilatna kiselina Mylan 75 mg/75 mg filmom obložene tablete Jedna filmom obložena tableta sadrži 75 mg klopidogrela (u obliku klopidogrelhidrogensulfata) i 75 mg acetilsalicilatne kiseline (ASK).
Aluminium perforated unit dose blisters with desiccant layer containing 28 or 30 film-coated tablets.
28 ili 30 filmom obloženih tableta u perforiranim aluminijskim blisterima s jediničnim dozama, sa slojem sredstva za sušenje.
Clopidogrel/Acetylsalicylic acid Mylan 75 mg/100 mg film-coated tablets Each film-coated tablet contains 75 mg of clopidogrel (as hydrogen sulphate) and 100 mg of acetylsalicylic acid (ASA).
Klopidogrel/acetilsalicilatna kiselina Mylan 75 mg/100 mg filmom obložene tablete Jedna filmom obložena tableta sadrži 75 mg klopidogrela (u obliku klopidogrelhidrogensulfata) i 100 mg acetilsalicilatne kiseline (ASK).
Clopidogrel/Acetylsalicylic acid Mylan 75 mg/100 mg film-coated tablets are pink, oval-shaped biconvex, tablets imprinted with CA3 on one side of the tablet and M on the other side.
Klopidogrel/acetilsalicilatna kiselina Mylan 75 mg/100 mg filmom obložene tablete su ružičaste, ovalne, bikonveksne tablete s utisnutom oznakom „CA3“ na jednoj i „M“ na drugoj strani.
METHOD AND ROUTE OF ADMINISTRATION
Upravljanje vozilima i strojevima
Clopidogrel/Acetylsalicylic acid Mylan 75 mg/100 mg film-coated tablets EU/1/19/1395/006 - Cartons of 28 film coated tablets in aluminium blister packs EU/1/19/1395/007 - Cartons of 30 film coated tablets in aluminium blister packs EU/1/19/1395/008 - Cartons of 28 x 1 (unit dose) film coated tablets in aluminium blister packs EU/1/19/1395/009 - Cartons of 30 x 1 (unit dose) film coated tablets in aluminium blister packs EU/1/19/1395/010 - Cartons of 100 film coated tablets in HDPE bottle packs
Klopidogrel/acetilsalicilatna kiselina Mylan 75 mg/100 mg filmom obložene tablete EU/1/19/1395/006 - kutije s 28 filmom obloženih tableta u aluminijskim blisterima EU/1/19/1395/007 - kutije s 30 filmom obloženih tableta u aluminijskim blisterima EU/1/19/1395/008 - kutije s 28 x 1 (jedinična doza) filmom obloženih tableta u aluminijskim blisterima
Each film-coated tablet contains 75 mg clopidogrel (as hydrogen sulphate) and 75 mg acetylsalicylic acid.
Jedna filmom obložena tableta sadrži 75 mg klopidogrela (u obliku klopidogrelhidrogensulfata) i 75 mg acetilsalicilatne kiseline.
Clopidogrel/Acetylsalicylic acid Mylan 75 mg/100 mg film-coated tablet The active substances are clopidogrel and acetylsalicylic acid.
Klopidogrel/acetilsalicilatna kiselina Mylan 75 mg/100 mg filmom obložene tablete Djelatne tvari su klopidogrel i acetilsalicilatna kiselina.
If you get any side effects, talk to your doctor or pharmacist.
Prije uzimanja bilo kojeg lijeka posavjetujte se sa svojim liječnikom ili ljekarnikom.
Clopidogrel/Acetylsalicylic acid Mylan 75 mg/75 mg film-coated tablets Clopidogrel/Acetylsalicylic acid Mylan 75 mg/100 mg film-coated tablets clopidogrel/acetylsalicylic acid
Klopidogrel/acetilsalicilatna kiselina Mylan 75 mg/75 mg filmom obložene tablete Klopidogrel/acetilsalicilatna kiselina Mylan 75 mg/100 mg filmom obložene tablete klopidogrel/acetilsalicilatna kiselina
Clopidogrel was not shown to alter fertility in animal studies.
U ispitivanjima na životinjama, klopidogrel nije imao utjecaj na plodnost.
Clopidogrel/Acetylsalicylic acid Mylan 75 mg/75 mg tablets
Klopidogrel/acetilsalicilatna kiselina Mylan 75 mg/75 mg tablete
Thrombocytopenia, leucopenia, eosinophilia
Urikozurici (benzbromaron, probenecid, sulfinpirazon)
Aluminium blisters with desiccant layer containing 28 or 30 film-coated tablets.
28 ili 30 filmom obloženih tableta u aluminijskim blisterima, sa slojem sredstva za sušenje.
Clopidogrel/Acetylsalicylic acid Mylan 75 mg/75 mg film-coated tablets Hypromellose
Klopidogrel/acetilsalicilatna kiselina Mylan 75 mg/75 mg filmom obložene tablete Hipromeloza
EU/1/19/1395/001 - 28 film coated tablets in aluminium blister packs EU/1/19/1395/002 - 30 film coated tablets in aluminium blister packs EU/1/19/1395/003 - 28 x 1 (unit dose) film coated tablets in aluminium blister packs EU/1/19/1395/004 - 30 x 1 (unit dose) film coated tablets in aluminium blister packs EU/1/19/1395/005 - 100 film coated tablets in HDPE bottle packs
EU/1/19/1395/001 - kutije s 28 filmom obloženih tableta u aluminijskim blisterima EU/1/19/1395/002 - kutije s 30 filmom obloženih tableta u aluminijskim blisterima EU/1/19/1395/003 - kutije s 28 x 1 (jedinična doza) filmom obloženih tableta u aluminijskim blisterima